BSEM offering history
Every offering-related filing in BioStem Technologies, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 14 filings back to Feb 1, 2016.
| Date | Filing | What it means | |
|---|---|---|---|
| Jul 29, 2026 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
| Oct 28, 2025 | RW → | WITHDRAWN | Registration withdrawn |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
BSEM offering FAQ
When did BSEM last execute an offering?
No executed-offering document (424B pricing supplement or 8-K item 3.02) appears in the 14 filings EDGAR returns for BioStem Technologies, Inc., reviewed back to 2016-02-01.
When did BSEM last announce or register an offering?
The most recent registration is a S-1 filed 2026-07-29. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.